PharmaSource Says It Did Not Know Dexcom Sensors Were Intended for Destruction
What's happening
PharmaSource said it was unaware that Dexcom glucose sensors it purchased had been designated for destruction rather than resale. The dispute follows concerns that stolen or improperly distributed medical devices had entered the marketplace.
What's changing / Business impact
The situation has raised questions about supply-chain oversight and how medical devices move through secondary markets. Both companies are facing scrutiny as regulators and stakeholders seek to understand how the products were redistributed.
Why this matters
Continuous glucose monitors play an important role in diabetes management. Patients rely on these devices for accurate readings, making supply-chain integrity especially important. The case highlights the challenges healthcare companies face in tracking products after they leave official distribution channels.